<qa>  What is the true incidence of transplant-related mortality at 1 year?Based on published results of unmodified transplants from HLA-matched siblings applied to patients with AML in first or second morphologic complete remission, a significant improvement in results with a graft modified as specified in this protocol would be expected if disease-free survival DFS at 6 months was greater than 75, the true incidence of transplant-related mortality at 1 year was less than 30, and the DFS rate at 2 years was greater 70 for patients transplanted in first remission and less than 60 for patients transplanted in second remission. Additional secondary endpoints include the following: graft failure rate and incidences of acute grade II-IV and chronic graft-versus-host disease GVHD. Additionally, the trial will have target specific doses of CD34 progenitors and CD3 T cells to be obtained following fractionation with the CliniMACS system. Based on the results of this trial, a Phase III trial comparing T cell depleted peripheral blood stem cell transplants PBSCT with unmanipulated bone marrow or unmanipulated PBSCT will be designed. 